… ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … children,” said Daniel de Boer, chief executive officer of ProQR. “This designation for sepofarsen underscores the …
… ProQR to Highlight a Growing Pipeline During a Research & … the Netherlands, March 01, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … Miami Beach Hotel in Miami Beach, FL, USA at 2:35pm ET. R&D Day On March 14, 2016 starting at 10am ET the company …
… ProQR Announces Enrollment Has Started in Global Phase 1b … said Daniel A. de Boer, Chief Executive Officer of ProQR. "Since the foundation of the company 3 years ago our … study will also assess sweat chloride, weight gain, CFQ-R Respiratory Symptom Score and lung function, measured by …
… ProQR Announces Clearance of IND to Start Clinical Trial of … & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, Chief Executive Officer of ProQR. “QR-421a has shown promising activity in both the …
… ProQR Receives Fast Track Designation from the FDA for QR-110 … for Leber’s Congenital Amaurosis Type 10 Key Updates ProQR receives Fast Track designation by the U.S. Food and … which there is currently nothing available,” said Noreen R. Henig, Chief Medical Officer of ProQR. “We are also …
… ProQR Announces Closing of Initial Public Offering and Full … The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) announced today the … securities laws of any such state or jurisdiction. About ProQR We are an innovative biopharmaceutical company engaged …
… ProQR Announces Positive Top-Line Results from the Phase 1/2 … Retinal Disease community as a whole,” said Stephen R. Russell, MD, Schrage Professor of Ophthalmology and Visual … Executive Vice President of Research & Development of ProQR, said, “We are very pleased with the data reported from …
… ProQR Announces Japanese Axiomer™ Patent Upheld Following … (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … 2023 with the Japanese Patent Office by a strawman against ProQR’s granted patent JP 7244922 , which is related to the …
… ProQR Therapeutics Announces $8.1 Million in New Funding from … (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through … who have the R270X mutation in MECP2 gene, and is based on ProQR’s proprietary Axiomer RNA editing platform. Axiomer can …
… ProQR Announces Positive Top-Line Results from a Phase 1b … improvement of CF respiratory symptoms, as measured by CFQ-R RSS, was observed in 3 out of 4 multiple dose groups with a … said Noreen R. Henig, M.D, Chief Medical Officer at ProQR. “I want to thank the entire CF community including …